These two FTSE 250 companies have been flying over the past five years. Is there a danger they could suddenly come crashing back to earth?
Spirax spirals
Spirax-Sarco Engineering (LSE: SPX) is a multinational engineering group made up oftwo businesses, Spirax Sarco for steam specialities and Watson-Marlow for niche peristaltic pumps and associated fluid path technologies. Its job is to help customers save energy and water, boost efficiency, improve product quality and make improvements in plant health, safety and regulatory compliance.
The companysshare price has soared a dizzying70% in the past 12 months and is up 180% over five years. Earlier this month it comforted investors by reporting thatanticipated, organic sales growth in the first four months of the year beat lastyears. It expects sales and profits to rise 5% and 8% respectively year-on-year, at broadly constant currency rates.
Cash is king
Spirax-Sarco Engineering is growing through acquisition, buyingsteam specialities business Gestra for 160m earlier this month, and long-term target US electrical products provider Chromalox for 319m, in acash and debt-free transaction last week. The purchase fits nicely alongside its existing operations and the companys share price bounced more than 8% on Friday.
There is just one sticking point: the company currently trades at a pricey 33.25 times earnings. This is partly justified by its growth prospects, with earnings per share (EPS) forecast to rise a hefty 19% this calendar year, and another 8% in 2018. Even that will only reduce the valuation to 26.5 times earnings. Revenues and profits look set to rise strongly, although this cash generative business only yields 1.33%. It nonetheless looks a tempting buy, with a net cash balance of 60m prior to the Gestraacquisition, although possibly oneto save for a market dip.
Get real
Assura Group (LSE: AGR) is the UKs leading healthcare real estate investment trust, specialising in designing, building and managing a portfolio of nearly 400 GP surgery buildings and primary care centres. Recent share price growth has been so-so and the stock is up just 7% over the past year. But over five years it has grown 109%, and this success has lifted its valuation to more than 25 times earnings, which is somewhat heady.
Itsrecent full-year results appear to justify that kind of valuation, with continued growth across its portfolio, rents, profits and dividend. Assuraposted a21.2% increase in investment property to 1.3bn, 16.6% increase in rent roll to 74.4m and a 20% rise in EPS. Investors were duly rewarded with a 9.8% increase in its fully covered dividend, from 2.05p to 2.25p.
Primary investment
Assura also has a strong pipeline with 153m of acquisition and development opportunities, andmanagement stating that the overwhelming need for improved primary care premises underpins the companys future. Both the Conservatives and Labour have madecommitments to improve NHS buildings in the next parliament.
The companys EPS are forecast to grow steadily, by 7% in the year to 31 March 2018, and another 7% in the year afterwards. With a forecast yield of 4%, Assura offers an attractive income stream as well as positivegrowth prospects. There are good reasons why itisnt dirt cheap.
Brexit talks begin just 11 days after next month’s election. Whether you voted Leave or Remain, your portfolio will not escape the fallout.
This BRAND NEW special Motley Fool report sets out exactly what Brexit means for your portfolio, and how you can take advantage by picking up top company stocks at bargain basement prices.
Don’t just fret about Brexit any longer but click here to read this no obligation report. It will be yours in moments and won’t cost you a penny.